The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy
Current Treatment Options in Oncology · 2024
DOI: 10.1007/s11864-024-01246-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, 2024. Verfasst von Heng Dong und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, 311121,…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Molecular Targeted Therapy, Immunotherapy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
OPINION STATEMENT: Hepatocellular carcinoma (HCC) is a common type of tumor worldwide. The development of systemic treatment of advanced HCC has remained stagnant for a considerable period. During the last years, a series of new treatment regimens based on the combination of immunotherapeutic drugs and targeted drugs have been gradually developed, increased the objective response rate (ORR), overall survival (OS), and progression free survival (PFS) of HCC patients. Among the different combination therapy groups, atezolizumab plus bevacizumab and sintilimab plus IBI-305 seem to have unique advantages, while head-to-head comparisons are still needed. A comprehensive understanding of the developments, the ongoing clinical trials and the mechanisms of combination of immunotherapy and targeted therapy might lead to the development of new combination strategies and solving current challenges such as the molecular biomarkers, the clinical administration order of drugs and the second-line treatments after combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy and Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, 311121, People's Republic of China.
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of…
- School of Pharmacy and Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, 311121, People's Republic of China. chenjx@hznu.edu.cn.
- Laboratory of Cancer Genomics, Division of Cellular and Molecular Research, National Cancer Centre, Singapore, 169610, Singapore. chenjx@hznu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Dong, H., Zhang, Z., Ni, M., Xu, X., Luo, Y., Wang, Y., Zhang, H., & Chen, J. (2024). The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-024-01246-9
Vancouver
Dong H, Zhang Z, Ni M, Xu X, Luo Y, Wang Y, et al. The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy. Current Treatment Options in Oncology. 2024. doi:10.1007/s11864-024-01246-9
BibTeX
@article{Dong2024,
author = {Dong, Heng and Zhang, Zhengguo and Ni, Mengjie and Xu, Xiaoyun and Luo, Yifeng and Wang, Yaru and Zhang, Haiyun and Chen, Jianxiang},
title = {The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy},
journal = {Current Treatment Options in Oncology},
year = {2024},
doi = {10.1007/s11864-024-01246-9}
}
EUVIMED